Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Cancer. 2017 Jul 31;123(22):4325–4336. doi: 10.1002/cncr.30896

Figure 1. Overall survival amongst elderly rectal adenocarcinoma patients stratified by treatment received: chemoradiation then surgery, surgery the chemoradiation, short-course radiation then surgery, surgery alone, and no treatment.

Figure 1

Kaplan-Meier curve showing the overall survival (OS) estimates of the entire cohort of patients as stratified by treatment group, with the number at risk below the x-axis. Among all patients, the 3 and 5-year overall survival estimated rates for patients receiving CRT+S were 69.0% (95% CI 65.9–71.9%) and 49.6% (95% CI 45.7–53.3%) respectively. The 3 and 5-year overall survival estimated rates for patients receiving surgery then chemoradiation were 60.5% (95%CI: 50.8–68.9%) and 47.4% (36.9%–57.2%) respectively. The 3 and 5-year survival estimated rates for patients receiving short-course radiation followed by surgery were 52.7% (95%CI: 42.8–61.7%) and 36.0% (95%CI: 26.3–45.7%) respectively. The 3 and 5-year overall survival estimated rates for patients receiving definitive surgery alone were 40.3% (95% CI: 36.5–44.1%) and 24.3% (95%CI: 20.6–28.1%) respectively. The 3 and 5-year overall survival estimated rates for patients not receiving therapy of were 9.1% (95% CI 6.3–12.6%) and 5.7% (95% CI 3.5–8.8%) respectively.